Roche's "T-A" program significantly improved the overall survival of patients with liver cancer

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death worldwide.
, more than 750,000 people worldwide suffer from hepatocellular carcinoma each year, most of them in Asia and almost half in China.
HCC is mainly caused by chronic hepatitis B or C viral infections, as well as cirrhosis caused by alcohol consumption or non-alcoholic fatty hepatitis.
is a heavy-duty immuno checkpoint inhibitor developed by Roche, and Avetin is an anti-angiogenesic drug.
anti-angiogenesic drugs not only have the effect of cutting off the nutritional supply of tumors, but also can play a role in changing the micro-environment of tumors and improving immunotherapy.
in recent years, a combination of checkpoint inhibitors/anti-angiogenic drugs has been approved by the FDA.
"T-A" combination was approved by the FDA last May, making it the first treatment in more than a decade to improve total patient survival and non-progressity survival compared to previous standard therapies.
last October, China's State Drug Administration (NMPA) also approved the combination therapy.
IMbrave150 is a global Phase 3, multi-center, open study designed to assess the role of the "T-A" program in patients with non-removable hepatocellular carcinoma who have not previously received systematic treatment.
after a median duration of 15.6 months of follow-up, the latest analysis results show that the "T-A" scheme can reduce the risk of death by 34%, the median total survival period of 19.2 months, better than the previous standard scheme of 13.4 months (HR s 0.66; 95% CI: 0.52-0.85); In the Chinese sub-group, the median total lifetime reached 24.0 months, better than the previous standard scheme of 11.4 months (HR=0.53; 95% CI: 0.35-0.80）。
Professor Qin Shuxuan, the leading Chinese researcher in the IMbrave150 study and vice president of the Chinese Society of Clinical Oncology (CSCO), said: "In October 2020, the 'T-A' immunization joint program was officially approved in China and has now been listed as a recommended therapy by several authoritative clinical guidelines, which fully demonstrates the breakthrough significance of this joint treatment.
It is worth mentioning that although the Chinese sub-group in the IMbrave 150 trial and expansion test has a higher rate of hepatitis B infection, as well as large blood vessel invasion/liver metastasis, A fetal protein ≥400 ng/ml and other prognostic adverse factors, still achieved excellent results, especially the medium total survival period reached 24.0 months, achieved a new breakthrough in the treatment of advanced liver cancer, a milestone for the vast number of Patients in China! Dr Levi Garraway, Roche's chief medical officer and head of global product development, said: "The data confirm that the 'T-A' programme shows a longer total lifetime in existing phase 3 clinical trials of non-removable hepatocellular carcinoma.
, the program has been approved in more than 60 countries and regions around the world, 'T-A' can bring patients a double improvement in survival and quality of life, is a major advance in the treatment of hepatocellular carcinoma.
: This article is intended to introduce medical and health research, not treatment options recommended.
if you need guidance on treatment options, visit a regular hospital.